https://www.selleckchem.com/pr....oducts/pimicotinib.h
The cumulative incidence of cancer progression was 50% and 69%, respectively, at 6months and 12months. Eleven patients (65%) died over the median follow-up period of 4.6months (interquartile range, 1.5-13.2months) from the time of ICI initiation, with cancer progression being the most common cause of death. ICIs can be used as individualized therapy in selected patients who have undergone solid organ transplantation but more studies are needed to determine how best to use these agents to improve outcomes further. ICIs can be used as
Like
Comment
Share
